Recent Advances in Imaging of Dopaminergic Neurons for Evaluation of Neuropsychiatric Disorders
Open Access
- 1 January 2012
- journal article
- review article
- Published by Hindawi Limited in Journal of Biomedicine and Biotechnology
- Vol. 2012, 1-14
- https://doi.org/10.1155/2012/259349
Abstract
Dopamine is the most intensely studied monoaminergic neurotransmitter. Dopaminergic neurotransmission plays an important role in regulating several aspects of basic brain function, including motor, behavior, motivation, and working memory. To date, there are numerous positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiotracers available for targeting different steps in the process of dopaminergic neurotransmission, which permits us to quantify dopaminergic activity in the living human brain. Degeneration of the nigrostriatal dopamine system causes Parkinson’s disease (PD) and related Parkinsonism. Dopamine is the neurotransmitter that has been classically associated with the reinforcing effects of drug abuse. Abnormalities within the dopamine system in the brain are involved in the pathophysiology of attention deficit hyperactivity disorder (ADHD). Dopamine receptors play an important role in schizophrenia and the effect of neuroleptics is through blockage of dopamine D2receptors. This review will concentrate on the radiotracers that have been developed for imaging dopaminergic neurons, describe the clinical aspects in the assessment of neuropsychiatric disorders, and suggest future directions in the diagnosis and management of such disorders.Keywords
Funding Information
- National Science Council (NSC99-3111-Y-042A-013)
This publication has 120 references indexed in Scilit:
- A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's DiseaseMolecular Therapy, 2010
- Imaging for early differential diagnosis of parkinsonismThe Lancet Neurology, 2010
- Imaging dopamine's role in drug abuse and addictionNeuropharmacology, 2009
- Dopamine Cell Implantation in Parkinson's Disease: Long-Term Clinical and 18F-FDOPA PET OutcomesJournal of Nuclear Medicine, 2009
- Positron Emission Tomography Imaging Demonstrates Correlation between Behavioral Recovery and Correction of Dopamine Neurotransmission after Gene TherapyJournal of Neuroscience, 2009
- Dopamine transporter levels in cocaine dependent subjectsDrug and Alcohol Dependence, 2008
- Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patientsJournal of Neural Transmission, 2004
- [ 123 I]β-CIT and SPECT in essential tremor and Parkinson's diseaseJournal of Neural Transmission, 1998
- Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- Preparation and biodistribution of [125I]IBZM: A potential CNS D-2 dopamine receptor imaging agentInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1988